Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study

OBJECTIVE: To report the efficacy and safety of erenumab among patients with episodic migraine (EM) who were unsuccessful on 2 to 4 preventive treatments observed at week 64 of the open-label extension phase (OLEP) of A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines...

Descripción completa

Detalles Bibliográficos
Autores principales: Goadsby, Peter J., Reuter, Uwe, Lanteri-Minet, Michel, Paiva da Silva Lima, Gabriel, Hours-Zesiger, Peggy, Fernandes, Chrystel, Wen, Shihua, Tenenbaum, Nadia, Kataria, Aditi, Ferrari, Michel D., Klatt, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205467/
https://www.ncbi.nlm.nih.gov/pubmed/33910942
http://dx.doi.org/10.1212/WNL.0000000000012029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205467/
https://www.ncbi.nlm.nih.gov/pubmed/33910942
http://dx.doi.org/10.1212/WNL.0000000000012029

Ejemplares similares